Company / EPS (Diluted)
MBX Biosciences, Inc. EPS (Diluted) History
FY2023-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$5.82
FY2024
5-year range
-$31.96 / -$5.82
FY2023-FY2024
Trend
+81.8%
vs FY2023
Sector context
#184 of 204
Health Care
What the data says
Among 204 Health Care companies, MBX Biosciences, Inc. is in the bottom 10% for eps (diluted).
Based on SEC 10-K filings.
-5.82 in FY2024.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 10% in Health CareTop 90% of 204This company -$5.82 Sector average -$0.89
▼
-556.7% below sector average
Key checks
Key Insights
- In FY2024, eps (diluted) increased 81.8% year-over-year.
- Ranks #184 out of 204 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 9.64 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$5.82 | +81.8% |
| FY2023 | -$31.96 | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026